Mutamycin (Mitomycin)

MUTAMYCIN®

Bristol

Mitomycin

Antineoplastic

Action And Clinical Pharmacology: Mitomycin was investigated at first as an antibiotic in Japan. It was then found to be active as an antineoplastic agent. It selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The exact point of mitomycin attachment to DNA remains unknown. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Mitomycin is rapidly cleared from the plasma after i.v. administration with a biphasic plasma elimination curve. Mitomycin is widely distributed but does not appear to cross the blood brain barrier. After i.v. injection of 30, 20 or 10 mg of mitomycin, the maximal serum concentrations were 2.4, 1.7 and 0.52 µg/mL respectively. Serum half-life after a 30 mg bolus injection is 17 minutes. Clearance is effected primarily by metabolism in the liver, but metabolism occurs in other tissues as well. In general, the smaller the dose, the more rapidly blood levels of mitomycin decreased.

Approximately 10% of a dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases with increasing doses. In children, excretion of i.v. administered mitomycin is similar.

Mitomycin is not appreciably absorbed from the urinary bladder following intravesical administration. Serial plasma samples from 55 patients treated with doses of 20 and 40 mg of mitomycin by intravesical instillation were assayed. There was no mitomycin detectable (assay limit 10 and 100 ng/mL) in any plasma samples collected during and 30 minutes post-therapy at any dose.

Indications And Clinical Uses: In the palliative treatment as an adjunct to surgery, radiation, or chemotherapy for adenocarcinoma of the stomach and colon.

Mitomycin as a single agent is indicated as topical therapy for superficial (no invasion beyond the lamina propria) transitional cell carcinoma of the urinary bladder. Efficacy has been demonstrated both in patients who have had no prior intravesical chemotherapy and in those who have failed such therapy with thiotepa or other antineoplastic agents.

Contra-Indications: Patients who have demonstrated hypersensitivity or an idiosyncratic reaction to it, or any component of its formulation, in the past.

Mitomycin is contraindicated in patients with thrombocytopenia, leukopenia, coagulation disorder, or an increased bleeding tendency due to other causes.

Mitomycin is contraindicated for intravesical administration in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past.

Manufacturers’ Warnings In Clinical States: Caution: Mitomycin is a potent drug and should be used only by physicians experienced with cancer chemotherapeutic drugs (see Precautions). Blood counts should be taken weekly. Mitomycin must be discontinued or dosage reduced upon evidence of abnormal depression of the bone marrow, or the development of significant renal or pulmonary toxicity.

It is recommended that mitomycin be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Since facilities for necessary laboratory studies must be available, hospitalization of patients is recommended.

Mitomycin should not be administered to any patient with a white blood cell count below 4 000 mmor a platelet count below 150 000 mm or those with potentially serious infections.

Bone marrow depression, notably thrombocytopenia and leukopenia is the most severe toxicity (see Adverse Effects). Thrombocytopenia may contribute to hemorrhage and leukopenia to overwhelming infection in an already compromised, poor risk patient and may result in death.

In the treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit versus the risk of toxicity. Studies have shown that mitomycin is carcinogenic in animals.

Pregnancy: Safe use of mitomycin in pregnant women has not been established. Mitomycin has known teratogenic properties in animals, therefore, the benefits derived from the use of mitomycin must be weighed against the hazards involved.

Lactation: It is not known if mitomycin is excreted in human milk. It is recommended that women receiving mitomycin not breast-feed because of the potential for serious adverse reactions from mitomycin in nursing infants.

Precautions: Mitomycin should be administered, preferably, to patients who are hospitalized.

It should be used with extreme caution in patients with significant impairment of renal function.

Since mitomycin has a high incidence of bone marrow depression, particularly thrombocytopenia and leukopenia, dose adjustment according to nadir count may be required. The following studies should be obtained repeatedly during therapy and for at least 8 weeks following therapy: platelet count, prothrombin time, bleeding time, white blood count and differential. The persistence of thrombocytopenia below 150 000/mmor a significant prolongation of prothrombin time or bleeding time or a WBC below 4 000/mmis an indication for the termination of therapy.

Hemolytic Uremic Syndrome (HUS), a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia and irreversible renal failure has been reported in patients receiving mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses 60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined (see Adverse Effects).

Patients should be advised of the potential toxicity of this drug, particularly bone marrow depression. A low incidence of septicemic deaths, as a result of leukopenia attributable to the drug, have been reported. Patients should be instructed of the relevant symptomatology and advised of the importance of promptly notifying their physicians of the development of these symptoms.

Patients receiving mitomycin should be observed for evidence of renal toxicity. Mitomycin should not be given to patients with a serum creatinine greater than 1.7 mg/dL (150 mol/L).

Mitomycin-associated pulmonary events have occurred infrequently but can be severe and life-threatening. Cases have been reported with both single-agent therapy and combination chemotherapy. Dyspnea and nonproductive cough are the usual presenting symptoms. Radiographic evidence of interstitial infiltrates may or may not be present. If other etiologies have been eliminated, a diagnosis of mitomycin-related pulmonary toxicity may be made. Corticosteroids have been employed in treatment, but their therapeutic value has not been determined.

Signs and symptoms of pneumonitis associated with mitomycin may be reversed if appropriate therapy is instituted early. The use of mitomycin should be discontinued. Corticosteroids have been reported by several authors to expedite symptomatic relief.

Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids in patients who had previously or simultaneously received mitomycin. The onset of this acute respiratory distress has occurred within minutes to hours after the vinca alkaloid injection. The total number of doses for each drug has varied considerably. Bronchodilators, corticosteroids and/or oxygen have produced symptomatic relief.

A few cases of adult respiratory distress syndrome have been reported in patients receiving mitomycin in combination with other chemotherapeutic agents who were being maintained perioperatively at Fi02 concentrations greater than 50%. Therefore, caution should be exercised, and only enough oxygen to provide adequate arterial saturation should be used since oxygen itself can be toxic to the lungs. Careful attention should be paid to fluid balance and overhydration should be avoided.

Adverse Reactions: Hematologic: The most serious and most common toxicity of mitomycin is bone marrow suppression. Thrombocytopenia and/or leukopenia may occur anytime within 8 weeks after initiation of therapy, with an average time of 4 weeks. The return to normal counts after cessation of therapy was within 10 weeks. In a recent study, at a dose of 20 mg/mevery 6 to 8 weeks, by itself or in combination with 5-fluorouracil, leukopenia occurred in 74 of 94 patients, with 10 being in the life-threatening category and thrombocytopenia occurring in 68 of 94 patients, with 18 being in the life-threatening category. In a previous study, at doses of 0.5 mg/kg/day for 5 days and repeating once monthly, or 0.25 mg/kg every 2 weeks, leukopenia and/or thrombocytopenia occurred in 605 of 937 patients. About 25% of the leukopenic or thrombocytopenic episodes did not resolve. Mitomycin produces cumulative myelosuppression.

Skin and Mucous Membrane: Cellulitis at the injection site has been reported and is occasionally severe. Stomatitis and alopecia also occur frequently. Rashes are rarely reported. The most important dermatological event is necrosis and consequent sloughing of tissue which results if the drug is extravasated during injection.

Extravasation may occur with or without an accompanying stinging or burning sensation and even if there is adequate blood return when the injection needle is aspirated. There have been reports of delayed erythema and/or ulceration occurring either at or distant from the injection site, weeks to months after mitomycin, even when no obvious evidence of extravasation was observed during administration. Skin grafting has been required in some of the cases.

Pulmonary Toxicity: Refer to section on pulmonary toxicity in Precautions.

Renal: A small number of patients in clinical trials demonstrated a significant rise in BUN from a baseline pretherapy. There appeared to be no correlation between total dose administered or duration of therapy and renal toxicity. Seventy-five percent of the patients with a definite renal toxicity had evidence of metastatic disease. The data, to date, are inconclusive as far as a direct relationship of mitomycin to renal toxicity.

Hemolytic Uremic Syndrome (HUS): This serious complication of chemotherapy consisting of microangiopathic hemolytic anemia (hematocrit 25%), thrombocytopenia (100 000/mm, and irreversible renal failure (serum creatinine 1.6 mg/dL or 140 mol/L) has been reported in patients receiving systemic mitomycin. Most of these patients received long-term therapy (6 to 12 months) with mitomycin in combination with fluorouracil and doxorubicin; however, some patients received mitomycin in combination with other drugs or were treated for less than 6 months. Microangiopathic hemolysis with fragmented red blood cells seen on peripheral blood smears has occurred in 98% of the patients with the syndrome. Other less frequent complications of the syndrome may include pulmonary edema (65%), neurologic abnormalities (16%), and hypertension. Exacerbation of the symptoms associated with HUS has been reported in some patients receiving blood product transfusions. The incidence of the syndrome has not been defined. A high mortality rate (52%) has been associated with this syndrome (see Precautions).

The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs. Less frequently, HUS has also been reported in patients receiving combinations of cytotoxic drugs not including mitomycin. Of 83 patients studied, 72 developed the syndrome at total doses exceeding 60 mg of mitomycin. Consequently, patients receiving 60 mg of mitomycin should be monitored closely for unexplained anemia with fragmented cells on peripheral blood smear, thrombocytopenia, and decreased renal function.

Acute Adverse Effects: Fever, hemolytic anemia, anorexia, stomatitis, hypoglycemia, mucositis, and diarrhea have occurred.

Other adverse effects that have been reported during mitomycin therapy have been: headache, blurring of vision, confusion, drowsiness, syncope, fatigue, weakness, edema, thrombophlebitis, hematemesis, nausea, vomiting, weight loss, ataxia and pain. These do not appear to be dose-related and it was unclear whether they were drug-related or due to the primary or metastatic disease process.

Genitourinary irritation following intravesical administration indicated dysuria, cystitis, nocturia and increased frequency of micturition, hematuria and other symptoms of local irritation. Approximately 25% of the patients treated experienced irritative symptoms, but not all were unequivocally drug-related and may have been symptoms of the disease.

Dermatitis occurred in approximately 10% of the patients treated. It was commonly manifested as palmar rash with desquamation, generally appearing on the extremities and less often on the trunk, and also as genital rash. Topical steroids have been employed, but their therapeutic value has not been determined.

Symptoms And Treatment Of Overdose: Symptoms and Treatment: No specific antidote for mitomycin is known. Management of overdosage would include general supportive measures to sustain the patient through any period of toxicity that might occur.

Dosage And Administration: Mitomycin should be given with care to avoid extravasation of the compound into the tissue. If extravasation occurs, cellulitis, ulceration and sloughing may result.

To reconstitute a vial, add Sterile Water for Injection as listed in the Reconstitution Table.

Shake well until dissolved. If the product does not dissolve immediately, shake under warm tap water for approximately 2 minutes until a solution is obtained.

I.V.: After full hematological recovery from any previous chemotherapy, either of the following Dosage Schedules may be used at 6 to 8 week intervals. Because of cumulative myelosuppression, patients should be re-evaluated after each course of mitomycin and the dose reduced if the patient has experienced any toxicities (see Guide to Dosage Adjustment). Doses greater than 20 mg/mdo not demonstrate increased effectiveness and are more toxic than lower doses.

(1) 20 mg/mi.v. as a single dose via a functioning i.v. catheter.

(2) 2 mg/mday i.v. for 5 days. After a drug-free interval of 2 days, 2 mg/mday for 5 days, thus making the total initial dose of 20 mg/mgiven over 10 days.

Intravesicle: 20 to 40 mg intravesically at a concentration of 1 mg/mL in sterile water once per week for 8 weeks. Patients are advised to abstain from liquids for 12 hours prior to therapy. The patient is catheterized, bladder drained and mitomycin instilled. The solution should be retained for 2 hours. If desired, the patient may rotate positions every 15 minutes, for maximum area-contact.

No repeat dosage should be given until leukocyte count has returned to 3 000 and platelet count to 75 000/mm

When mitomycin is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly. If the disease continues to progress after 2 courses of mitomycin, the drug should be stopped since chances of response are minimal.

Stability: Store mitomycin at room temperature (15 to 30°C) and protect from light.

When reconstituted with Sterile Water for Injection to a concentration of 0.5 mg/mL, mitomycin is stable for 14 days when refrigerated (2 to 8°C), or for 7 days at room temperature (15 to 30°C). Protect from light.

When reconstituted with Sterile Water for Injection to a concentration of 1 mg/mL, mitomycin is stable for 7 days at room temperature (25°C). If undissolved particles appear after reconstitution, warm the vial slightly with shaking. Solutions of mitomycin at a concentration of 1 mg/mL, should not be stored under refrigeration since precipitation may occur.

The combination of mitomycin (5 to 15 mg) and heparin (1 000 to 10 000 units) in 30 mL of 0.9% Sodium Chloride Injection is stable for 48 hours at room temperature (15 to 30°C).

Handling and Disposal: Preparation of Mutamycin should be done in a vertical laminar flow hood (Biological Safety Cabinet-Class II).

Personnel preparing Mutamycin should wear PVC gloves, safety glasses, disposable gowns and masks.

All needles, syringes, vials and other materials which have come in contact with Mutamycin should be segregated and incinerated at 1 000°C or more. Sealed containers may explode sealed. Intact vials should be returned to the Manufacturer for destruction. Proper precautions should be taken in packaging these materials for transport.

Personnel regularly involved in the preparation and handling of Mutamycin should have bi-annual blood examinations.

Availability And Storage: Each vial contains: mitomycin 5 mg and 20 mg as sterile lyophilized powder. Nonmedicinal ingredients: mannitol. Store at room temperature (15 to 30°C) and protect from light.

MUTAMYCIN® Bristol Mitomycin Antineoplastic

Connected Diseases :

Bladder Cancer

General Illness Information Medical Term: Bladder carcinoma Common Name: Bladder cancer Description: Bladder cancer is a malignant tumor invasion of the mucosa or wall of…